Apotex Receives FDA’s Drug Shortage Assistance Award
Apr 19, 2023Recognized for efforts in resolving shortage of varenicline tablets
Toronto, Ontario (April 19, 2023) - Apotex Inc. is pleased to announce that it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA) in recognition of the company’s substantial efforts to resolve a shortage of varenicline tablets.
When the US market experienced a shortage of 0.5 mg and 1 mg varenicline tablets, and in order to reduce the impact to patients from an ongoing recall, the FDA temporarily exercised regulatory flexibility and discretion with respect to Apotex’s importation of Health-Canada approved Apo-Varenicline tablets in the U.S. The award also recognizes the submission and ultimate approval of an abbreviated new drug application (ANDA) for varenicline tablets in the U.S. market.
“We’re proud to receive this important award from the FDA, and to be recognized for our commitment to public health” said Allan Oberman, President and Chief Executive Officer, Apotex. “Our flexible supply chain and North American manufacturing model helped ensure an uninterrupted supply of medicines and demonstrates our focus on increasing access to affordable, high quality products.”
This award recognizes the efforts of drug companies and manufacturers who have worked in cooperation with FDA, and have implemented strategies to help provide a steady supply of medically necessary drugs at a time when critical drug shortages pose a substantial public health threat – delaying, and in some cases even denying, critically needed care for patients. Working with drug companies and manufacturers like Apotex, the FDA helped prevent 317 drug shortages in 2021.
About Apotex Inc.
Apotex is a proudly Canadian-based, global health company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. It exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India. For more information, visit www.apotex.com.
-30-
All media enquiries :
Jordan Berman
Vice-President, Global Corporate Affairs
Apotex Inc.
[email protected]
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.